Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

, regulatory submissions, manufacturing facility and product demand, that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of the Technosphere Insulin System, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, intellectual property matters and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MannKind Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30, June 30, June 30,


'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...b., Nov. 5 Transgenomic,...inancial results for the quarter ended September 3...nted in the tables that follow. ,, Third Quart...$366,000 or $0.01 per share for the third quarter ...0.01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)...Calif., Nov. 5 WaferGen ...ding developer of state-of-the-art genetic analysi... Ph.D. has joined the company,s Scientific Advisor... and commercializing novel molecular diagnostics f... the development of computational biology systems ...
(Date:11/5/2009)... Brooke Sanders brings a new look to Pro...B) November 5, 2009 -- Professional Reprographics,...cs company is pleased to present Brooke Sanders to...aphics/PR specialist. The addition of Brooke to th...th within Professional Reprographics., , ,Brooke b...
(Date:11/4/2009)... ROCKVILLE, Md., Nov. 4 Zyngenia, ...used on next-generation antibody drug development,...n Series A funding from New Enterprise Associates ...firms. The capital will be used to create novel, m... two or more biological targets with a single agen...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
... RDEA119 Produced Significant Beneficial Effect in...hritis - - RDEA594 Shows Promise as an Effect...ea Biosciences, Inc.,(Nasdaq: RDEA ) today announ...ead mitogen-activated ERK kinase (MEK) inhibitor, ...al models of arthritis. In addition, the Company,w...
...YNBROOK, N.Y., June 10 BioSpecifics,Technologies ...t sold an,aggregate of 100,000 unregistered shares...ggregate proceeds to BioSpecifics of $1,500,000. T...ors on June 9, 2008. The shares,were sold in a com...e,market price., BioSpecifics Technologies Corp. ...
... EVANSTON, Ill. --- More than 30 years ago, when ...developed a powerful new sensing technique, he nev...t treasures in the Art Institute of Chicago,s coll... in the museum,s exhibition "Watercolors by Winslo...olor "For to be a Farmer,s Boy," painted in 1887, ...
Other Biology Technology:Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 2Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 3Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 4Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 5Northwestern chemist investigates lost reds in Homer painting 2
(Date:11/4/2009)...Oct. 26 BIO-key Internat...n finger-based biometric identification software i...at the AABB TXPO conference being held at the New ... BIO-key will provide hands-on product demonstrati...ogy in booth #424. Also, at 5 PM on Monday, Octobe...
(Date:11/4/2009)...lif., Nov. 4 GenVault Corporation ... M.D., Ph.D., has joined its Board of Directors. ...the Salk Institute, is an acclaimed physician-scie... Salk Institute, Dr. Brody served as president of ...he National Academy of Engineering and the Institu...
(Date:11/3/2009)... FL (November 4, 2009) For more than 25 years, al...h ( Strombus gigas ) have been unsuccessfuluntil n...ing techniques to produce beaded (nucleated) and n...e been developed by scientists from Florida Atlant...ute (HBOI). With less than two years of research a...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3New Non Biological Synthetic Replikins 28TM 29 Vaccines Shown to Be Effective and Fast 3B WorldVaccines 28TM 29 Ltd Formed for Testing and Distributi 14531 1New Non Biological Synthetic Replikins 28TM 29 Vaccines Shown to Be Effective and Fast 3B WorldVaccines 28TM 29 Ltd Formed for Testing and Distributi 14531 2New Non Biological Synthetic Replikins 28TM 29 Vaccines Shown to Be Effective and Fast 3B WorldVaccines 28TM 29 Ltd Formed for Testing and Distributi 14531 3AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 1AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 2AEterna Zentaris to Raise US 245 5 Million from Institutional Investors at US 241 20 Per Share 14528 3ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 1ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 2ThermoGenesis Names Jorge Artiles Vice President Chief Quality and Regulatory Affairs Officer 5574 3
...s in Moravia, Czech Republic, excavated more than ... through modern radiocarbon dating, to be the olde...arly modern humans in Europe. , A team of research...m the University of Vienna in Austria and from the...conducted the first successful direct dating of th...
...amed 60,000 years ago? ,Now you can find out by pa...tracing the genetic and migratory history of the h...l over the world can supply their DNA to the Genog...f Arizona in Tucson will do the genetic analysis. ...aking to unravel the origins and migratory history...
...Syndrome (HGPS) -- a disease associated with prema... to findings by scientists at the National Cancer ...f Health (NIH). Using specially modified segments ...om Misteli, PhD, reversed the abnormalities seen i... the key protein, lamin A. By demonstrating that H...
Other Biology News:Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2The biggest family tree ever 2The biggest family tree ever 3Cellular Defects in Premature Aging Disease are Reversible 2Cellular Defects in Premature Aging Disease are Reversible 3
Mouse Anti-Simian Virus 5 Monoclonal Antibody, Unconjugated from AbD Serotec
Beagle Serum from Innovative Research
Mouse Anti-Bovine TROPONIN I (CARDIAC & SKELETAL) Monoclonal Antibody, Unconjugated, Clone C5 from AbD Serotec
Donkey Serum from CHEMICON
Biology Products: